These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 5436353)

  • 1. Rapid correction of AHF deficiency by antihemophilic factor-method four, with special reference to inhibitors.
    Shanbrom E
    Bibl Haematol; 1970; 34():52-9. PubMed ID: 5436353
    [No Abstract]   [Full Text] [Related]  

  • 2. A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate. Treatment of classical hemophilia and hemophilia with inhibitors.
    Brinkhous KM; Shanbrom E; Roberts HR; Webster WP; Fekete L; Wagner RH
    JAMA; 1968 Aug; 205(9):613-7. PubMed ID: 5695099
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of aliphatic amino acid precipitated antihemophilic factor in therapy of hemophilia.
    Brinkhous KM; Wagner RH; Roberts HR; Webster WP
    Bibl Haematol; 1968; 29():1104-8. PubMed ID: 5700305
    [No Abstract]   [Full Text] [Related]  

  • 4. Glycine-precipitated antihemophilic factor concentrates and their clinical use.
    Wagner RH; Roberts HR; Webster WP; Shanbrom E; Brinkhous KM
    Thromb Diath Haemorrh Suppl; 1968; 35():41-8. PubMed ID: 5761073
    [No Abstract]   [Full Text] [Related]  

  • 5. [Technic of obtaining the antihemophilic factors VIII and IX and their clinical application].
    Triginer J; Vila M; Vicente Arangüena P
    Sangre (Barc); 1979; 24(5-C):937-41. PubMed ID: 121169
    [No Abstract]   [Full Text] [Related]  

  • 6. Concentrated antihemophilic factor (AHF) from outdated blood.
    Weaver RA; Gabriel DA; Langdell RD
    Transfusion; 1967; 7(3):168-73. PubMed ID: 6025692
    [No Abstract]   [Full Text] [Related]  

  • 7. [Relationships of factor VIII (antihemophilic globulin) and its weak inhibitors with the spleen. Effect of adrenaline on splenectomized subjects, on splenomegaly and on patients presenting a weak factor VIII inhibitor].
    Mayer G; Kalogjera V; Oberling F; Mayer S; Waitz R
    Haematol Lat; 1971; 13(3):185-206. PubMed ID: 5097059
    [No Abstract]   [Full Text] [Related]  

  • 8. [The dosage of antihemophilic globulin, or antihemophilic plasma as well as Cohn's fraction I in factor VIII deficiency].
    Hrubisková K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1970; 93(3):363-8. PubMed ID: 4195283
    [No Abstract]   [Full Text] [Related]  

  • 9. The physiologic basis for therapy of classic hemophilia (factor 8 deficiency) and related disorders. Combined clinical staff conference at the National Institutes of Health.
    Ann Intern Med; 1967 Oct; 67(4):856-82. PubMed ID: 5299081
    [No Abstract]   [Full Text] [Related]  

  • 10. Report of a clinical trial of a Canadian preparation of antihemophilic factor.
    Magnin AA; Johnson SE
    Can Med Assoc J; 1979 Aug; 121(4):422-4, 427. PubMed ID: 466616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the response of patients with classic hemophilia to transfusion with concentrates of antihemophilic factor. A difference in the half-life of antihemophilic factor as measured by procoagulant and immunologic techniques.
    Bennett B; Ratnoff OD
    J Clin Invest; 1972 Oct; 51(10):2593-6. PubMed ID: 4626847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of large-scale fractionation methods. 3. Preparation of a factor VIII concentrate of intermediate-purity.
    James HL; Wickerhauser M
    Vox Sang; 1972; 23(5):402-12. PubMed ID: 5077739
    [No Abstract]   [Full Text] [Related]  

  • 13. The development of the technology and capacity for the production of factor VIII for the treatment of hemophilia A.
    Aronson DL
    Transfusion; 1990 Oct; 30(8):748-58. PubMed ID: 2120808
    [No Abstract]   [Full Text] [Related]  

  • 14. Factor VIII inhibitors in haemophilia.
    Lancet; 1983 Apr; 1(8327):742-3. PubMed ID: 6132087
    [No Abstract]   [Full Text] [Related]  

  • 15. Total dental extraction in a patient with F VIII inhibitor.
    Stenbjerg S; Tauris P; Skottun T; Jørgensen J
    Thromb Res; 1980 Jun; 18(6):889-93. PubMed ID: 6774444
    [No Abstract]   [Full Text] [Related]  

  • 16. Preparation of and clinical experience with antihemophilic factor concentrates.
    Johnson AJ; Karpatkin MH; Newman J
    Thromb Diath Haemorrh Suppl; 1968; 35():49-59. PubMed ID: 5317364
    [No Abstract]   [Full Text] [Related]  

  • 17. [Isolation of antihemophilic factor in human blood].
    VAN CREVELD S; HOORWEG PG; DEN OTTOLANDER GJ; VEDER HA
    Ned Tijdschr Geneeskd; 1955 Jul; 99(31):2269-75. PubMed ID: 13253742
    [No Abstract]   [Full Text] [Related]  

  • 18. Ultrapure plasma factor VIII produced by anti-F VIII c immunoaffinity chromatography and solvent/detergent viral inactivation. Characterization of the Method M process and Hemofil M antihemophilic factor (human).
    Griffith M
    Ann Hematol; 1991 Sep; 63(3):131-7. PubMed ID: 1932287
    [No Abstract]   [Full Text] [Related]  

  • 19. Factor VIII inhibitor by-passing activity (FEIBA) in the management of patients with factor VIII inhibitors.
    Preston FE; Dinsdale RC; Sutcliffe DJ; Bardhan G; Wyld PJ; Hamlyn JF
    Thromb Res; 1977 Nov; 11(5):643-51. PubMed ID: 929513
    [No Abstract]   [Full Text] [Related]  

  • 20. Monoclate: a purified antihemophilic factor.
    Med Lett Drugs Ther; 1988 Jan; 30(756):1-2. PubMed ID: 3121992
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.